Conversion from intravenous to oral mexiletine in the acute management of repetitive ventricular arrhythmia. 1985

L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal

We evaluated the safety and efficacy of intravenous mexiletine and a method for converting from intravenous to oral mexiletine therapy. Fifteen patients with repetitive ventricular ectopy (13 had ventricular tachycardia) received intravenous mexiletine at a rate of 10 mg/min for 30 to 60 minutes. Ventricular ectopy was suppressed with minimal side effects in 10 of 15 subjects. Oral mexiletine was begun immediately after completion of the intravenous infusion at a dose of 10 mg/kg/24 hr in the 10 responders to intravenous therapy. In eight, the oral dose was effective in suppressing the arrhythmia, but it induced side effects in three of them. In one of these three, dose reduction resulted in adequate arrhythmia control with acceptable toxicity. In the two who did not respond to the original dose, a larger dose (15 mg/kg/24 hr) induced arrhythmia control with acceptable side effects in one subject. Thus rapid control of nonsustained repetitive ventricular arrhythmia can be achieved with intravenous mexiletine in about two thirds of patients, and conversion to oral therapy can often be achieved smoothly without significant arrhythmia recurrence.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008297 Male Males
D008801 Mexiletine Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. KO-1173,KO1173,KOE-1173,Mexiletene,Mexiletine Hydrochloride,Mexitil,Mexitil PL,Mexityl,Novo-Mexiletine,KO 1173,KOE 1173,KOE1173,Novo Mexiletine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D011437 Propylamines Derivatives of propylamine (the structural formula NH2CH2CH2CH3).
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005117 Cardiac Complexes, Premature A group of cardiac arrhythmias in which the cardiac contractions are not initiated at the SINOATRIAL NODE. They include both atrial and ventricular premature beats, and are also known as extra or ectopic heartbeats. Their frequency is increased in heart diseases. Ectopic Heartbeats,Extrasystole,Premature Beats,Premature Cardiac Complexes,Cardiac Complex, Premature,Extrasystoles,Premature Cardiac Complex,Beat, Premature,Beats, Premature,Complexes, Premature Cardiac,Ectopic Heartbeat,Heartbeat, Ectopic,Heartbeats, Ectopic,Premature Beat,Premature Cardiac Complices
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
April 1983, American heart journal,
L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
May 1984, American heart journal,
L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
January 1978, Annales de cardiologie et d'angeiologie,
L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
June 1984, La Clinica terapeutica,
L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
January 2022, Clinical and experimental nephrology,
L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
October 1964, Circulation,
L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
January 1984, European journal of clinical pharmacology,
L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
January 1987, Fundamental & clinical pharmacology,
L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
January 1982, La Clinica terapeutica,
L N Horowitz, and A M Greenspan, and S R Spielman, and S J Frye, and L A Yacone, and D T Lowenthal
October 1983, Annales de cardiologie et d'angeiologie,
Copied contents to your clipboard!